These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9302115

  • 1. Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression.
    Thalmann GN, Dewald B, Baggiolini M, Studer UE.
    J Urol; 1997 Oct; 158(4):1340-4. PubMed ID: 9302115
    [Abstract] [Full Text] [Related]

  • 2. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 3. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [Abstract] [Full Text] [Related]

  • 4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 5. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J, Crego M, Sabaté S, Salvador J, Palou J, Villavicencio H.
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [Abstract] [Full Text] [Related]

  • 6. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC.
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [Abstract] [Full Text] [Related]

  • 7. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P, Holmäng S.
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [Abstract] [Full Text] [Related]

  • 8. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y, Sawada Y, Inagaki T, Kohjimoto Y, Uekado Y, Shinka T.
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer.
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK.
    J Urol; 2002 Jan; 167(1):364-7. PubMed ID: 11743357
    [Abstract] [Full Text] [Related]

  • 10. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, Popov Z, Zafrani ES, Abbou CC, Chopin DK, de Medina SG.
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [Abstract] [Full Text] [Related]

  • 11. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A.
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [Abstract] [Full Text] [Related]

  • 12. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 13. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 14. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y, Nomata K, Noguchi M, Eguchi J, Koga S, Yamashita S, Hayashi M, Kanatake H.
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [Abstract] [Full Text] [Related]

  • 16. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW.
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [Abstract] [Full Text] [Related]

  • 17. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
    Hausladen DA, Wheeler MA, Altieri DC, Colberg JW, Weiss RM.
    J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
    [Abstract] [Full Text] [Related]

  • 18. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 19. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
    Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF.
    J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
    [Abstract] [Full Text] [Related]

  • 20. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P, Błaszczyk J, Fijałkowski P, Sierakowska-Fijałek A, Niemirowicz J, Kasprzak A, Baj Z.
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.